---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-24-000059"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:44:01.541283+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Q1 revenues $368.9M (-3.1%); GAAP EPS $(0.04); adj. EPS $0.55; guidance raised on Acclarent

## Summary
- Q1 revenues $368.9M (-3.1% reported, -2.5% organic; +1.6% organic ex-Boston); GAAP net loss $3.3M ($(0.04)/share) vs net income $24.2M ($0.29) prior year.
- Adjusted EPS $0.55 vs $0.74 prior year; adjusted EBITDA $71.8M (19.5% rev) vs $92.3M (24.2%).
- Acclarent acquisition closed April 1; FY2024 revenue guidance raised to $1.672-1.687B, adj. EPS guidance $3.01-3.11.
- Tissue Technologies revenue fell 15.3% driven by Boston recall; removing SurgiMend/PriMatrix relaunch from guidance due to audit findings.
- Codman Specialty Surgical grew 3.3% reported (4.4% organic); Neurosurgery up 6.3% organically, Instruments down 2.0%.

## SEC filing metadata
- accession: 0000917520-24-000059
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752024000059/0000917520-24-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752024000059/iart-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-24-000059
- JSON: https://secwatch.observer/filing/0000917520-24-000059.json
- Plain text: https://secwatch.observer/filing/0000917520-24-000059.txt

## Key facts
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported the quarter ended March 31, 2024 results: revenue $368.9 million, net income $(3.3) million, EPS $(0.04) per diluted share. Guidance raised.
  - Period: the quarter ended March 31, 2024
  - Revenue: $368.9 million
  - Net income: $(3.3) million
  - EPS: $(0.04) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: Total reported revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Organic growth excluding Boston was 1.6%. Revenue exceeded the outlook the Company provided in February. The Company reported GAAP gross margin of 56.1%, compared to 61.1% in the first quarter of 2023. Adjusted gross margin was 64.4%, compared to 67.3% in the prior year. Adjusted EBITDA for the first quarter of 2024 was $71.8 million, or 19.5% of revenue, compared to $92.3 million, or 24.2% of revenue, in the prior year. The Company reported a GAAP net loss of $(3.3) million, or $(0.04) per diluted share, in the first quarter of 2024, compared to a GAAP net income of $24.2 million, or $0.29 per diluted share, in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752024000059/0000917520-24-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.